Factors Involved in the Progression of Preclinical Atherosclerosis in People with Type 1 Diabetes

<b>Background/objectives:</b> Individuals with type 1 diabetes (T1DM) face an elevated risk of cardiovascular disease (CVD), yet the factors driving atherosclerosis remain unclear. This study aimed to assess factors associated with preclinical atherosclerosis development or progression in T1DM. <b>Methods:</b> We conducted a prospective study in T1DM individuals without established CVD, aged ≥40 years, with diabetic kidney disease and/or ≥10 years of T1DM plus another cardiovascular risk factor (CVRF). Baseline evaluation followed a standardized CV risk assessment protocol, including carotid ultrasound and cardiovascular risk estimation using the Steno Type 1 Risk Engine (ST1RE). Ultrasound was repeated after 3-5 years; progression was defined as an increase in plaque number. CVRF control was considered optimal when LDL-cholesterol was within target based on atherosclerotic burden, blood pressure <130/80 mmHg, HbA1c <7%, and non-smoking status. Logistic regression models identified predictors of progression. <b>Results:</b> We included 151 participants (55.6% women; mean age 49.8 ± 8.9 years; T1DM duration 27.3 ± 9.1 years); 42.4% had plaques at baseline. Over a follow-up of 5.22 ± 1.29 years, despite improved CVRF control (<i>p</i> < 0.05), 40.4% experienced progression. Older age (OR 1.38 [1.1-1.8]) and active smoking (OR 3.29 [1.4-7.5]) were significant predictors of progression. Baseline cardiovascular risk measured by the ST1RE independently predicted progression (OR 1.09 [1.03-1.15]) after adjusting for other CVRFs. Persistent smoking (OR 2.52 [1.06-5.99]) and baseline ST1RE (OR 1.06 [1.02-1.11]) remained significant after accounting for baseline and follow-up CVRFs. <b>Conclusions:</b> Despite improved CVRF control, atherosclerosis progression is common in T1D. ST1RE may help identify individuals at highest risk for targeted preventive strategies.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2025-08-25
DOI
https://doi.org/10.3390/jcm14176004
Primary Topic
Blood Pressure and Hypertension Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Factors Involved in the Progression of Preclinical Atherosclerosis in People with Type 1 Diabetes

Verónica Perea, Tonet Serés‐Noriega, Clara Viñals, Mónica Doménech et al.
Journal of Clinical Medicine
Blood Pressure and Hypertension Studies
article

Factors Involved in the Progression of Preclinical Atherosclerosis in People with Type 1 Diabetes

Verónica Perea, Tonet Serés‐Noriega, Clara Viñals, Mónica Doménech, Clara Solà, Irene Vinagre, Marga Giménez, Jesús Blanco, Ignacio Conget, Antonio Jesús Amor, Alex Mesa, Denisse Ayala, Montse Granados
article en

Abstract

<b>Background/objectives:</b> Individuals with type 1 diabetes (T1DM) face an elevated risk of cardiovascular disease (CVD), yet the factors driving atherosclerosis remain unclear. This study aimed to assess factors associated with preclinical atherosclerosis development or progression in T1DM. <b>Methods:</b> We conducted a prospective study in T1DM individuals without established CVD, aged ≥40 years, with diabetic kidney disease and/or ≥10 years of T1DM plus another cardiovascular risk factor (CVRF). Baseline evaluation followed a standardized CV risk assessment protocol, including carotid ultrasound and cardiovascular risk estimation using the Steno Type 1 Risk Engine (ST1RE). Ultrasound was repeated after 3-5 years; progression was defined as an increase in plaque number. CVRF control was considered optimal when LDL-cholesterol was within target based on atherosclerotic burden, blood pressure <130/80 mmHg, HbA1c <7%, and non-smoking status. Logistic regression models identified predictors of progression. <b>Results:</b> We included 151 participants (55.6% women; mean age 49.8 ± 8.9 years; T1DM duration 27.3 ± 9.1 years); 42.4% had plaques at baseline. Over a follow-up of 5.22 ± 1.29 years, despite improved CVRF control (<i>p</i> < 0.05), 40.4% experienced progression. Older age (OR 1.38 [1.1-1.8]) and active smoking (OR 3.29 [1.4-7.5]) were significant predictors of progression. Baseline cardiovascular risk measured by the ST1RE independently predicted progression (OR 1.09 [1.03-1.15]) after adjusting for other CVRFs. Persistent smoking (OR 2.52 [1.06-5.99]) and baseline ST1RE (OR 1.06 [1.02-1.11]) remained significant after accounting for baseline and follow-up CVRFs. <b>Conclusions:</b> Despite improved CVRF control, atherosclerosis progression is common in T1D. ST1RE may help identify individuals at highest risk for targeted preventive strategies.

Journal of Clinical MedicineVol. 14(17)
Universidad de Zaragoza (ES), Hospital de Sant Pau (ES), Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (ES), University Hospital Mútua de Terrassa (ES), Hospital Clínic de Barcelona (ES), Biomedical Research Institute (US), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
Openalex Percentile: Top 65%
Blood Pressure and Hypertension Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.